FDA warned Hong Qiangxing Shenzhen Electronics after an inspection found quality-system violations in TENS, muscle stimulator, and blood pressure monitor manufacturing.
What happened
FDA inspected the Shenzhen, China facility from August 4 to August 7, 2025. The investigator found violations of the Quality System regulation, including inadequate software validation, design change and validation records, nonconforming product handling, CAPA, complaint and medical device report (MDR) evaluation, and product identification. FDA said several of the firm's responses did not fully address retrospective reviews and systemic corrections.
What FDA found
The firm did not adequately verify and validate the operating software for TENS and PMS Model SM9109A, a repeat violation from 2016.
21 CFR 820.30(g)Design change records for TENS/PMS and remote controller models lacked adequate documentation of the change, its reason, and its impact.
21 CFR 820.30(i)Design verification and validation records lacked sample-size rationale and raw data, and validation samples were not made under defined production conditions.
21 CFR 820.30(f), (g), (j)The firm did not document dispositions or justifications for use of nonconforming product, a repeat violation from 2016.
21 CFR 820.90(a)CAPA procedures did not ensure quality data were analyzed, and two CAPAs were not adequately investigated or verified for effectiveness.
21 CFR 820.100(a)Complaints were not adequately investigated or evaluated for MDR, and in-process units and obsolete materials were not properly identified.
21 CFR 820.198(a); 21 CFR 820.60
What FDA wants
FDA asks the firm to respond in writing within 15 business days with the specific steps, documentation, and timetables to correct the violations and prevent recurrence, and to provide English translations of non-English documents.
Who should pay attention
- distributors and brands selling TENS, muscle stimulators, or blood pressure monitors made by this firm
- companies relying on this contract manufacturer for device design or production
- quality teams managing complaint, MDR, and CAPA programs for similar devices
This is a summary. Read the original letter on fda.gov.